Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

Summary

A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL065 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (AMN).

Timeline

Start

2023-09

Primary completion

2024-09

Completion

2024-09

Outcome

Outcome not reported

Stopped (Business): “Funding unavailable”

Drugs

Indications